By Joel Kahn, MD, FACC
Topics: Joel Kahn, MD, FACC
In this short video, family practitioner Dr. George Stokes explains the better outcomes he’s achieved by going beyond traditional approaches to vascular health.
Topics: George Stokes, MD
Topics: Jack Wolfson, DO, FACC
Topics: Jack Wolfson, DO, FACC
Topics: Joel Kahn, MD, FACC, Kristine Burke, MD
Topics: Kristine Burke, MD
Topics: Joel Kahn, MD, FACC
At 600,000 fatalities a year, CVD accounts for 25% of American deaths. Stroke kills another 130,000.1 The precursor to most of these deaths is atherosclerosis: the development of plaque in the arterial wall.
While some plaque is relatively stable, it is the unstable plaque that causes most events.2 This more vulnerable plaque is liable to erupt and deposit its contents into the bloodstream, causing dangerous clots.
Numerous cellular, animal and human studies have been conducted to evaluate the biological activities, mode of mechanisms, and therapeutic benefits of Arterosil, a patent-pending nutraceutical. Studies include:
Download Arterosil's Research Summary here.
*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure or prevent any disease.
U.S. Patent No. 11,135,238. International Patents Pending.
© 2022 Calroy Health Sciences. All rights reserved.